Jane Street Group LLC Decreases Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Jane Street Group LLC cut its position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 42.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,514 shares of the company’s stock after selling 11,240 shares during the quarter. Jane Street Group LLC’s holdings in Entrada Therapeutics were worth $248,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in TRDA. US Bancorp DE purchased a new position in shares of Entrada Therapeutics in the third quarter valued at $42,000. SG Americas Securities LLC purchased a new position in shares of Entrada Therapeutics in the third quarter valued at $156,000. Acadian Asset Management LLC boosted its stake in shares of Entrada Therapeutics by 135.1% in the second quarter. Acadian Asset Management LLC now owns 13,367 shares of the company’s stock valued at $190,000 after purchasing an additional 7,682 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Entrada Therapeutics by 34.7% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company’s stock valued at $226,000 after purchasing an additional 3,644 shares during the period. Finally, BayBridge Capital Group LLC purchased a new position in shares of Entrada Therapeutics in the third quarter valued at $464,000. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

Entrada Therapeutics Price Performance

TRDA opened at $14.65 on Friday. The stock has a market capitalization of $548.20 million, a PE ratio of 9.21 and a beta of -0.12. The firm’s fifty day moving average price is $18.50 and its 200 day moving average price is $16.88. Entrada Therapeutics, Inc. has a 12-month low of $11.35 and a 12-month high of $21.79.

Insiders Place Their Bets

In other Entrada Therapeutics news, insider Natarajan Sethuraman sold 1,409 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $20.01, for a total transaction of $28,194.09. Following the sale, the insider now directly owns 163,588 shares of the company’s stock, valued at approximately $3,273,395.88. This represents a 0.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Bioventures 2018 L.P. Mpm sold 22,935 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $20.77, for a total transaction of $476,359.95. Following the sale, the insider now directly owns 4,402,849 shares in the company, valued at $91,447,173.73. This trade represents a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 42,281 shares of company stock valued at $861,999. Company insiders own 7.59% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TRDA. Roth Mkm assumed coverage on shares of Entrada Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $29.00 target price for the company. HC Wainwright upped their price target on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Roth Capital raised shares of Entrada Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Finally, Oppenheimer upped their price target on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, November 6th.

Entrada Therapeutics Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.